Building a robust pipeline to fight cancer

Our goal is to establish a sustainable clinical pipeline of novel and differentiated oncology programs geared towards achieving superior efficacy while minimizing the burden of side effects for patients. T cell engagers and ADCs will continue to be the main pillars of VERAXA’s pipeline strategy. At the same time, our expertise and capabilities can be applied to other formats, and we aim to explore emerging synergies between existing and novel antibody modalities. With our expertise and capabilities, we develop novel antibody-based drug modalities for the treatment of cancer.

Current VERAXA Pipeline

Program

Discovery

Preclinical

Phase I

Phase II

Indication

Partner

VXA-102 (BiTAC-TCE)

EpCAM x TAA × CD3

Lung, Colon, Pancreatic Cancer

Proprietary

VXA-101 (BiTAC-TCE)

CD38 x SLAMF7 x CD3

Proprietary

VXA-221 (BsADC)

n.d.

Lung, Breast Cancer

Proprietary

VXA-103 (BiTAC-TCE)

n.d.

Solid tumors

Proprietary

VXA-104 (BiTAC-TCE)

n.d.

Solid tumors

Proprietary

VXA-222 (BsADC)

n.d.

Solid tumors

Proprietary

VXA-301 (BiTAC-ADC)

n.d.

Solid tumors

Proprietary

VXA-901 (mAb)

FLT3

AML

Proprietary

VXA-210/211 (ADC)

HER2

Breast Cancer

Proprietary

VXA-901 - A novel therapeutic option for elderly AML patients

Acute myeloid leukemia (AML) is an aggressive cancer that mainly affects the elderly. Despite improvements, younger and fitter patients still tend to benefit more than older and less fit individuals. Treatment options for elderly patients and those who are not fit for intensive chemotherapy and stem cell transplantation are limited. The need for better therapies for older and unfit patients is growing.

FLT-3 is overexpressed in the majority of AML blasts

VXA-901 binds to primary blasts irrespective of mutation in FLT3
Optimized Fc-part induces ADCC via strong binding to NK cells

Distinct and complementary Mode of Action

VXA-901 can be combined with the first line of therapy
No ADCC effect on FLT-low expressing healthy bone marrow-derived HSPCs

Promising phase-1 clinical trial results

VXA-901 is safe and well tolerated in AML patients
Promising signs of monotherapy efficacy even in heavily pre-treated patients